Ancestry and pharmacogenetics of antileukemic drug toxicity
Open Access
- 30 January 2007
- journal article
- Published by American Society of Hematology in Blood
- Vol. 109 (10) , 4151-4157
- https://doi.org/10.1182/blood-2006-10-054528
Abstract
Treatment-related toxicity in acute lymphoblastic leukemia (ALL) can not only be life threatening but may also affect relapse risk. In 240 patients,Keywords
This publication has 46 references indexed in Scilit:
- Population stratification confounds genetic association studies among LatinosHuman Genetics, 2005
- Pharmacogenetics of outcome in children with acute lymphoblastic leukemiaBlood, 2005
- Down syndrome and leukemia: New insights into the epidemiology, pathogenesis, and treatmentPediatric Blood & Cancer, 2004
- Age Is a Risk Factor for Chemotherapy-Induced Hepatopathy With Vincristine, Dactinomycin, and CyclophosphamideJournal of Clinical Oncology, 2004
- Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemiaBlood, 2004
- Homocysteine, Pharmacogenetics, and Neurotoxicity in Children With LeukemiaJournal of Clinical Oncology, 2003
- Prognostic significance of the null genotype of glutathione S-transferase-T1 in patients with acute myeloid leukemia: increased early death after chemotherapyLeukemia, 2002
- Long-term results of large prospective trials in childhood acute lymphoblastic leukemiaLeukemia, 2000
- Successful treatment of acute lymphoblastic leukemia in a child with cystic fibrosisMedical and Pediatric Oncology, 1994
- Potential Long-Term Toxic Effects in Children Treated for Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 1989